A presentation by James Stevenson, PharmD, FASHP and Edward Li, PharmD, MPH, BCOP

A recent forecast estimates that by 2015, six out of the top ten selling drugs will be biologics, indicating that these products will be key drivers of the prescription drug market in the United States. The 2010 Affordable Care Act created a pathway for U.S. Food and Drug Administration approval of biosimilar products. This crucial step is expected to invigorate the biosimilars market, which is expected to shadow the booming biologics market, as patents for these agents begin to expire. This presentation describes how key issues regarding the clinical impact of biosimilar interchangeability are being addressed and how they are expected to impact the practice of pharmacy.

Share this on Twitter: